Pre-HCT complement activation markers in patients with and without SCD and in those who later did or did not develop TA-TMA. (A) Among patients with an available baseline pre-HCT sample (SCD = 22, non-SCD = 17, total = 39), there was no significant difference in pre-HCT levels of complement markers sC5b-9, C3a, C5a, or Bb in either the SCD or non-SCD cohorts. (B) There was no difference between those who later did develop TA-TMA (samples available, n = 7, all patients with SCD) and those who did not develop TA-TMA (n = 31). Dashed lines indicate upper and lower limits of normal. Box and whisker plots indicate the median and quartiles. Each value is represented by a red dot and the mean by a blue diamond.